Prelude Therapeutics/$PRLD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Prelude Therapeutics
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
- Ticker
- $PRLD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 79
- Headquarters
- Wilmington, United States
- Website
- preludetx.com
PRLD Metrics
BasicAdvanced
$371M
-
-$0.72
0.96
-
Price and volume
Market cap
$371M
Beta
0.96
52-week high
$6.83
52-week low
$1.17
Average daily volume
425K
Financial strength
Current ratio
4.072
Quick ratio
3.989
Long term debt to equity
0.111
Total debt to equity
0.132
Profitability
EBITDA (TTM)
-64.51
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-269.75%
Operating margin (TTM)
-294.76%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-27.15%
Return on equity (TTM)
-57.73%
Valuation
Price to revenue (TTM)
13.519
Price to book
2.77
Price to tangible book (TTM)
2.77
Price to free cash flow (TTM)
-9.116
Free cash flow yield (TTM)
-10.97%
Free cash flow per share (TTM)
-0.395
Growth
Revenue change (TTM)
220.34%
Earnings per share change (TTM)
-56.13%
3-year earnings per share growth (CAGR)
-32.59%
What the Analysts think about PRLD
Analyst ratings (Buy, Hold, Sell) for Prelude Therapeutics stock.
Analyst projections of the future price of Prelude Therapeutics stock.
Bulls say / Bears say
PRT13722 produced durable complete tumour regressions as a monotherapy in breast-cancer animal models, and Prelude reported activity in models resistant to existing treatments. These preclinical results give its KAT6A degrader a promising efficacy case to test in patients. (Prelude Therapeutics)
A Lilly supply agreement enables Prelude to test PRT13722 with abemaciclib and imlunestrant in its Phase 1 breast-cancer trial. That gives the company a practical route to assess combinations with established treatments, rather than relying on monotherapy alone. (Prelude Therapeutics)
Prelude's mutant-selective JAK2V617F drug is enrolling patients in Phase 1, while Incyte holds an option over the programme. If exercised, the option could bring a substantial milestone payment and provide external support for the asset. (SEC, StockAnalysis)
PRT13722 has not yet shown efficacy or safety in people: its reported tumour regressions and combination effects are from preclinical models, and Phase 1 enrolment is only due to start in the fourth quarter of 2026. Prelude's own materials place key readouts in 2027 and 2028, leaving a long wait for clinical proof. (Prelude Therapeutics, SEC)
The April 2026 share offering raised about $90 million but added substantial dilution: voting shares outstanding rose from 48.2 million at the end of 2025 to 65.0 million by June. Prelude still expects to fund operations only into the second quarter of 2028, and it has no product sales to rely on. (SEC)
The JAK2V617F programme's potential Incyte deal is not assured: Incyte's option remains a future decision, and the company recently discontinued its own similar JAK2V617F drug after delays. That raises uncertainty around external validation of this approach and the value of the option. (ApexOnco, StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
PRLD Financial Performance
Revenues and expenses
PRLD Earnings Performance
Company profitability
Upcoming events
No upcoming events
PRLD News
AllArticlesVideos
Funds containing PRLD
Fund name | Fund size | $PRLD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.